Roche rings Bicycle bell again, grabbing another cancer target
August 3, 2022
Roche’s Genentech unit has gone all in on its collaboration with UK biotech Bicycle Therapeutics, taking up an option on a second additional target in the area of cancer immunotherapy.
Bicycle’s bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and dosing easier.
Read the source article at pharmaphorum.com
2022-07-13 08:19:35
